Obesity Drug Causes Significant Weight Loss
- Here's a breakdown of the key information from the article about retatrutide:
- * What it is: Retatrutide is a new injectable drug being developed by Lilly for weight loss and perhaps for managing knee osteoarthritis.
- In essence, retatrutide appears to be a potentially more powerful weight loss drug than currently available options, but it may also come with a higher risk of side...
Retatrutide: A Promising New Weight loss Drug - Key Takeaways
Here’s a breakdown of the key information from the article about retatrutide:
* What it is: Retatrutide is a new injectable drug being developed by Lilly for weight loss and perhaps for managing knee osteoarthritis.
* How it works: It’s a “triple G” drug, meaning it targets three hormones – GLP-1, GIP, and glucagon – to regulate appetite and metabolism. This is different from Wegovy (GLP-1 only) and Zepbound (GLP-1 & GIP).
* Weight Loss results: Participants on the higher dose of retatrutide lost an average of around 70 pounds (29% of starting weight) after 68 weeks. This is considerably more than the average weight loss seen with Wegovy (15%) and Zepbound (21%).
* Knee Osteoarthritis Benefit: Retatrutide reduced pain scores related to knee osteoarthritis by up to 4.5 points on the WOMAC scale (almost 76% reduction).
* Side Effects/Drop-Out Rate: A higher percentage of participants taking retatrutide dropped out of the study early compared to the placebo group. Some reported stopping because the weight loss was too rapid. Specifically, 12% of those on the lower dose and 18% on the higher dose dropped out, compared to 4% on the placebo.
* Future Research: There haven’t been direct head-to-head trials comparing retatrutide to Wegovy and Zepbound yet.
In essence, retatrutide appears to be a potentially more powerful weight loss drug than currently available options, but it may also come with a higher risk of side effects or discomfort due to the speed of weight loss.